Articles related to BRAIN CANCER

There aren’t as many headlines concerning cell phones and brain cancer today, despite it formerly being a mainstay of frightened online fodder. Have people lost interest and simply unwilling to give up their phones? Have the studies on the topic allayed their concerns? Or is it that people just don’t believe cell phones are one of the numerous cancer hazards? Experts weigh in.

A Secondary Analysis of The N107C/CEC.3 (Alliance for Clinical Trials in Oncology/Canadian Cancer Trials Group) Randomized Clinical Trial When compared to WBRT, SRS alone resulted in less cognitive deterioration among long-term survivors. The link between late cognitive deterioration and WBRT was clinically significant. A significant decrease in cognition (2 SD) was linked to a decrease in overall QOL. WBRT, on the other hand, improved intracranial tumor control. This study provides detailed information about cognitive function in this patient population over time.

Researchers have identified a small molecule, named as SHP656, that can target the brain’s clock proteins and may prove effective for treating glioblastoma.

The prospective, open-label, single-arm, phase 2 TUXEDO-1 trial enrolled patients with HER2-positive breast cancer and newly diagnosed untreated brain metastases or brain metastases progressing after previous local therapy. Patients received trastuzumab deruxtecan intravenously at the standard dose of 5.4 mg per kg bodyweight once every 3 weeks. Fifteen patients received at least one dose of study drug. Two patients (13.3%) had a complete intracranial response, nine (60%) had a partial intracranial response and three (20%) had stable disease as the best intracranial response. There were no new safety signals.

Up to half of all patients with metastatic HER2+ breast cancer will eventually acquire brain metastases, which are associated with reduced overall survival and decreased quality of life. This comprehensive review examines current recommendations in 1st, 2nd, and later line therapies, discusses the status of novel agents, and provides recommendations to standardize care.

The Journal of Clinical Oncology has a heartfelt account of one family’s struggle to access medical records after the death of a child from a brain tumor. Closing down online access to medical records is a common practice at hospitals and healthcare clinics following the death of a patient, often to the pain of family members who still have questions and seek answers.